SANDS CHINA LTD's net profit for the second quarter increased by 2.5% year-on-year to US$1.79 billion.
Golden Sands China Limited (01928) announced that, in accordance with Generally Accepted Accounting Principles in the United States, Golden Sands China's second quarter of 2025...
SANDS CHINA LTD (01928) announced that, according to US Generally Accepted Accounting Principles, the net income for the second quarter of 2025 for Sands China increased by 2.5% from the second quarter of 2024 to $1.79 billion. The net revenue for the second quarter of 2025 for Sands China was $214 million, compared to $246 million in the second quarter of 2024.
The adjusted property EBITDA for Sands China in the second quarter of 2025 was $566 million, compared to $561 million in the second quarter of 2024.
The interest expense after deducting capitalized amounts for the second quarter of 2025 was $194 million, compared to $186 million in the same quarter last year. The weighted average debt balance for the second quarter of 2025 was $15.85 billion, compared to $14.73 billion in the second quarter of 2024. The weighted average cost of borrowing for the second quarter of 2025 was 4.8%, compared to 5.0% in the second quarter of 2024.
Related Articles
Shanghai Pharmaceuticals Holding (02607) plans to invest approximately 143 million yuan to acquire a 10% stake in a financial company.
ASCENTAGE-B (06855) completes the placement of 22 million shares, raising approximately HK$1.4925 billion net proceeds, with old shares sold before new shares.
Eli Lilly's (LLY.US) Alzheimer's drug Kisunla receives EU support and gets approved for use in specific patient populations.
Shanghai Pharmaceuticals Holding (02607) plans to invest approximately 143 million yuan to acquire a 10% stake in a financial company.
ASCENTAGE-B (06855) completes the placement of 22 million shares, raising approximately HK$1.4925 billion net proceeds, with old shares sold before new shares.
Eli Lilly's (LLY.US) Alzheimer's drug Kisunla receives EU support and gets approved for use in specific patient populations.
RECOMMEND
After Eight Consecutive Rate Cuts, the European Central Bank Pauses as Expected; Future Policy Direction Remains Murky
25/07/2025
U.S. President Makes First Official Visit to the Federal Reserve in Nearly 20 Years—What Did Trump and Powell Say?
25/07/2025
New Categories of Air Conditioners in Short Supply, Sales of Ice-Packed Handheld Fans Surge, China’s “Cooling Big Four” Explode in Popularity Across Europe
25/07/2025
